-+ 0.00%
-+ 0.00%
-+ 0.00%

Guardant Health Expects Improved Guardant360 Liquid CDx Reimbursement in 2027

PUBT·11/05/2026 23:30:15
Listen to the news
Guardant Health Expects Improved Guardant360 Liquid CDx Reimbursement in 2027
  • Guardant Health expects about 30% full-year 2026 growth for Guardant360 Liquid, fueled by its Smart Platform.
  • Third-quarter oncology revenue rose 25% to $231 million; testing volume increased 58% to 117,000.
  • Improved reimbursement for Guardant360 Liquid CDx remains on track for 2027, with ADLT designation expected in the first half.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.